Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer

Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide subsequent treatment selection. The potential utility of ctDNA in bladder cancer (BC) is bolstered by the high somatic mutation rate, meaning that very small numbers of genes or target regions can be informative. First reports indicate that analysis of ctDNA may represent a sensitive method for disease surveillance in patients with different stages of BC. Moreover, recent evidence suggests that ctDNA analysis reveals previously unknown genomic alterations in metastatic patients. Since some of these gene alterations represent therapeutic targets, ctDNA analysis provides an attractive tool to guide individualized therapy in BC


Todenhöfer, Tilmana; | Struss, Werner J.b; | Seiler, Rolandc | Wyatt, Alexander Williamb | Black, Peter C.b
[a]Department of Urology, University Hospital, Tübingen, Germany
[b]Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
[c] Inselspital Bern, Bern, Switzerlan


Journal: Bladder Cancer, vol. 4, no. 1, pp. 19-29, 2018